<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03560466</url>
  </required_header>
  <id_info>
    <org_study_id>LTS14424</org_study_id>
    <secondary_id>2017-003317-25</secondary_id>
    <secondary_id>U1111-1200-1757</secondary_id>
    <nct_id>NCT03560466</nct_id>
  </id_info>
  <brief_title>Assessment of the Safety and Efficacy of Dupilumab in Children With Asthma (Liberty Asthma Excursion)</brief_title>
  <official_title>One Year Study to Evaluate the Long-term Safety and Tolerability of Dupilumab in Pediatric Patients With Asthma Who Participated in a Previous Dupilumab Asthma Clinical Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Regeneron Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Objective:&#xD;
&#xD;
        -  To evaluate the long-term safety and tolerability of dupilumab in pediatric patients&#xD;
           with asthma who participated in a previous dupilumab asthma clinical study.&#xD;
&#xD;
        -  To evaluate the efficacy of dupilumab in children of 6 to &lt;12 years of age with&#xD;
           uncontrolled persistent asthma in the Japan sub-study.&#xD;
&#xD;
      Secondary Objectives:&#xD;
&#xD;
        -  To evaluate the long-term efficacy of dupilumab in pediatric patients with asthma who&#xD;
           participated in a previous dupilumab asthma clinical study.&#xD;
&#xD;
        -  To evaluate dupilumab in pediatric patients with asthma who participated in a previous&#xD;
           dupilumab asthma clinical study with regard to:&#xD;
&#xD;
             -  Systemic exposure.&#xD;
&#xD;
             -  Anti-drug antibodies (ADAs).&#xD;
&#xD;
             -  Biomarkers.&#xD;
&#xD;
        -  To evaluate the safety and tolerability of dupilumab in pediatric patients with asthma&#xD;
           in the Japan sub-study&#xD;
&#xD;
        -  To evaluate dupilumab in pediatric patients with asthma in the Japan substudy with&#xD;
           regard to:&#xD;
&#xD;
             -  Systemic exposure,&#xD;
&#xD;
             -  Anti-drug antibodies (ADAs),&#xD;
&#xD;
             -  Biomarkers&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study duration per participant is approximatively 64 weeks including a 52 weeks treatment&#xD;
      period and 12 weeks post treatment follow-up.&#xD;
&#xD;
      Japan substudy:&#xD;
&#xD;
      Study duration per participant is approximately 68 weeks including 3-5 weeks screening&#xD;
      period, 52 weeks treatment period and 12 weeks post treatment follow-up period.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">June 21, 2018</start_date>
  <completion_date type="Anticipated">October 2023</completion_date>
  <primary_completion_date type="Anticipated">October 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The number of patients experiencing any treatment emergent adverse event (TEAE)</measure>
    <time_frame>From Day 1 up to Week 64</time_frame>
    <description>The number of patients experiencing any TEAE.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Japan sub-study: Change from baseline in pre-bronchodilator percentage (%) predicted FEV1 at Week 12</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <description>Change from baseline in pre-bronchodilator percentage (%) predicted forced expiratory volume in 1 second (FEV1) at week 12.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Annualized rate of severe asthma exacerbation events during the treatment period</measure>
    <time_frame>From Day 1 up to Week 52</time_frame>
    <description>Annualized rate of severe asthma exacerbation events during the treatment period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in % predicted FEV1</measure>
    <time_frame>Baseline to Week 64</time_frame>
    <description>Change from baseline in % predicted FEV1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in absolute FEV1</measure>
    <time_frame>Baseline to Week 64</time_frame>
    <description>Change from baseline in absolute FEV1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in FVC</measure>
    <time_frame>Baseline to Week 64</time_frame>
    <description>Change from baseline in forced vital capacity (FVC).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in FEF 25 to 75%</measure>
    <time_frame>Baseline to Week 64</time_frame>
    <description>Change from baseline in forced expiratory flow (FEF) 25-75%.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum dupilumab concentrations</measure>
    <time_frame>From Day 1 up to Week 64</time_frame>
    <description>Serum dupilumab concentrations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of treatment-emergent antidrug antibodies (ADA) against dupilumab</measure>
    <time_frame>From Day 1 up to Week 64</time_frame>
    <description>Incidence of treatment-emergent ADA against dupilumab.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood eosinophil counts</measure>
    <time_frame>From Day 1 up to Week 64</time_frame>
    <description>Blood eosinophil counts.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum total IgE</measure>
    <time_frame>From Day 1 up to Week 64</time_frame>
    <description>Serum total IgE.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Japan sub-study: Annualized rate of severe asthma exacerbation events during the treatment period</measure>
    <time_frame>From Day 1 up to Week 52</time_frame>
    <description>Annualized rate of severe asthma exacerbation events, during the treatment period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Japan sub-study: Change from baseline in pre-bronchodilator % predicted FEV1 at Weeks 2, 4, 8, 24, 52, and 64</measure>
    <time_frame>Baseline to Week 2, 4, 8, 24, 52 and 64</time_frame>
    <description>Change from baseline in pre-bronchodilator % predicted FEV1 at Weeks 2, 4, 8, 24, 52, and 64.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Japan sub-stud: Change from baseline in absolute FEV1</measure>
    <time_frame>Baseline to Week 2, 4, 8, 12, 24, 52 and 64</time_frame>
    <description>Change from baseline in absolute FEV1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Japan sub-study: Change from baseline in FVC</measure>
    <time_frame>Baseline to Week 2, 4, 8, 12, 24, 52 and 64</time_frame>
    <description>Change from baseline in FVC.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Japan sub-study: Change from baseline in FEF 25-75%</measure>
    <time_frame>Baseline to Week 2, 4, 8, 12, 24, 52 and 64</time_frame>
    <description>Change from baseline in FEF 25-75%.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Japan sub-study: Change from baseline in ACQ-IA</measure>
    <time_frame>Baseline to Week 2, 4, 8, 12, 24, 36, 52, and 64</time_frame>
    <description>Change from baseline in Asthma Control Questionnaire-Interviewer Administered (ACQ-IA).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Japan sub-study: The number of patients experiencing any TEAEs</measure>
    <time_frame>From Day 1 up to Week 64</time_frame>
    <description>The number of patients experiencing any TEAEs.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Japan sub-study: Serum dupilumab concentrations</measure>
    <time_frame>From Day 1 up to week 64</time_frame>
    <description>Serum dupilumab concentrations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Japan sub-study: Incidence of treatment-emergent ADA against dupilumab</measure>
    <time_frame>From Day 1 up to Week 64</time_frame>
    <description>Incidence of treatment-emergent ADA against dupilumab.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Japan sub-study: Serum total immunoglobulin E (IgE)</measure>
    <time_frame>From Day 1 up to Week 64</time_frame>
    <description>Serum total immunoglobulin E (IgE).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Japan sub-study: Change from Baseline in FeNO</measure>
    <time_frame>Baseline to Weeks 2, 4, 8, 12, 24, 52, and 64</time_frame>
    <description>Change from Baseline in Fractional Exhaled Nitric Oxide (FeNO).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">365</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Dupilumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Doses of dupilumab will be administered every 2 weeks or every 4 weeks added to current controller medications for 52 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dupilumab (SAR231893/REGN668)</intervention_name>
    <description>Pharmaceutical form: solution for injection&#xD;
Route of administration: subcutaneous (sc)</description>
    <arm_group_label>Dupilumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Asthma controller therapies (incl. prednisone/prednisolone)</intervention_name>
    <description>Pharmaceutical form: powder, or solution, or pill&#xD;
Route of administration: inhaled, oral or parenteral</description>
    <arm_group_label>Dupilumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Asthma reliever therapies</intervention_name>
    <description>Pharmaceutical form: powder or solution&#xD;
Route of administration: inhaled</description>
    <arm_group_label>Dupilumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria :&#xD;
&#xD;
          -  Pediatric patients with asthma who completed the treatment in a dupilumab asthma trial&#xD;
             (EFC14153).&#xD;
&#xD;
          -  Signed written informed consent/assent. Specific for Brazil: EFC14153 patients from&#xD;
             Brazil, who prematurely discontinued Investigational Medicinal Product (IMP) to&#xD;
             receive Yellow Fever vaccine (a live attenuated vaccine) during Yellow Fever outbreak,&#xD;
             are allowed to be enrolled in LTS14424 after completing the required procedures in&#xD;
             EFC14153 (completion of remaining visits and procedures until end of treatment (EOT)&#xD;
             V28, considered as V1 for LTS14424).&#xD;
&#xD;
        Patients who are not able to complete their treatment in Study EFC14153 due to the COVID-19&#xD;
        pandemic will be allowed to enroll into Study LTS14424. Patients who enroll in LTS14424&#xD;
        after completing the EFC14153 EOS visit should have eligibility for LTS14424 reevaluated&#xD;
        including background medication check and laboratory assessments (including complete blood&#xD;
        count [CBC] with differential and basic chemistry) within 1 month prior to LTS14424 Visit&#xD;
        1.&#xD;
&#xD;
        For Japan sub-study&#xD;
&#xD;
          -  Signed written inform consent/assent&#xD;
&#xD;
          -  Children 6 to &lt;12 years of age, with a physician diagnosis of persistent asthma for&#xD;
             ≥12 months prior to screening&#xD;
&#xD;
          -  Blood eosinophil count ≥150 cells/μL or fractional exhaled nitric oxide (FeNO) ≥20&#xD;
             parts per billion (ppb) at screening visit (Visit 0).&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Any chronic lung disease other than asthma (eg, cystic fibrosis, bronchopulmonary&#xD;
             dysplasia) which may impair lung function.&#xD;
&#xD;
          -  Inability to follow the procedures of the study/noncompliance (eg, due to language&#xD;
             problems or psychological disorders).&#xD;
&#xD;
          -  Patients receiving concomitant treatment or required a new concomitant treatment&#xD;
             prohibited in the study.&#xD;
&#xD;
          -  Patients or his/her parent(s)/caregiver(s)/legal guardian(s) is related to the&#xD;
             Investigator or any Sub-Investigator, research assistant, pharmacist, study&#xD;
             coordinator, other staff thereof directly involved in the conduct of the study.&#xD;
&#xD;
          -  Patients who experienced any hypersensitivity reactions to dupilumab in a previous&#xD;
             dupilumab study, which, in the opinion of the Investigator, could indicate that&#xD;
             continued treatment with dupilumab may present an unreasonable risk for the patient.&#xD;
&#xD;
          -  Any abnormalities or adverse events at screening (last treatment visit in the study&#xD;
             EFC14153 will be the screening visit) that per Investigator judgment would adversely&#xD;
             affect patient's participation in this study or would require permanent IMP&#xD;
             discontinuation.&#xD;
&#xD;
          -  For female patients who have commenced menstruating at any time during the study and&#xD;
             are either:&#xD;
&#xD;
          -  Found to have a positive urine pregnancy test, or&#xD;
&#xD;
          -  Sexually active, not using an established acceptable contraceptive method.&#xD;
&#xD;
          -  Planned live, attenuated vaccinations during the study.&#xD;
&#xD;
          -  Patients with active autoimmune disease or patients using immunosuppressive therapy&#xD;
             for autoimmune disease (eg, juvenile idiopathic arthritis, inflammatory bowel disease,&#xD;
             systemic lupus erythematosus) at enrollment.&#xD;
&#xD;
        For Japan sub-study:&#xD;
&#xD;
          -  Any chronic lung disease other than asthma (eg, cystic fibrosis, bronchopulmonary&#xD;
             dysplasia) which may impair lung function.&#xD;
&#xD;
          -  Inability to follow the procedures of the study/noncompliance (eg, due to language&#xD;
             problems or psychological disorders).&#xD;
&#xD;
          -  Patients receiving concomitant treatment or required a new concomitant treatment&#xD;
             prohibited in the study at the screening and enrollment visits.&#xD;
&#xD;
          -  Patients who previously have been treated with dupilumab&#xD;
&#xD;
          -  Diagnosed with active parasitic infection (helminthes); suspected or high risk of&#xD;
             parasitic infection, unless clinical and (if necessary) laboratory assessments have&#xD;
             ruled out active infection before randomization&#xD;
&#xD;
          -  Known or suspected history of immunosuppression, including history of invasive&#xD;
             opportunistic infections (eg, histoplasmosis, listeriosis, coccidioidomycosis,&#xD;
             pneumocystosis, aspergillosis), despite infection resolution; or unusually frequent,&#xD;
             recurrent, or prolonged infections, per Investigator's judgment.&#xD;
&#xD;
        The above information is not intended to contain all considerations relevant to a patient's&#xD;
        potential participation in a clinical trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>7 Years</minimum_age>
    <maximum_age>12 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Sciences &amp; Operations</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Investigational Site Number :8400002</name>
      <address>
        <city>Gilbert</city>
        <state>Arizona</state>
        <zip>85234</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :8400012</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85274</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :8400001</name>
      <address>
        <city>Rolling Hills Estates</city>
        <state>California</state>
        <zip>90274</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :8400006</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110-1077</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :8400022</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68505</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :8400023</name>
      <address>
        <city>Great Neck</city>
        <state>New York</state>
        <zip>11021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :8400013</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :8400007</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :8400004</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28277</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :8400008</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :8400024</name>
      <address>
        <city>Edmond</city>
        <state>Oklahoma</state>
        <zip>73034</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :8400003</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :0320002</name>
      <address>
        <city>Caba</city>
        <state>Buenos Aires</state>
        <zip>C1122AAK</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :0320001</name>
      <address>
        <city>Caba</city>
        <state>Buenos Aires</state>
        <zip>C1414AIF</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :0320004</name>
      <address>
        <city>Buenos Aires</city>
        <zip>B1602DQD</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :0320003</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C1121ABE</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :0320006</name>
      <address>
        <city>Mendoza</city>
        <zip>5500</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :0360005</name>
      <address>
        <city>North Adelaide</city>
        <state>South Australia</state>
        <zip>5006</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :0760001</name>
      <address>
        <city>Porto Alegre</city>
        <state>Rio Grande Do Sul</state>
        <zip>90020-090</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :0760007</name>
      <address>
        <city>Porto Alegre</city>
        <state>Rio Grande Do Sul</state>
        <zip>90610-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :0760002</name>
      <address>
        <city>Sao Paulo</city>
        <state>São Paulo</state>
        <zip>04037-002</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :0760004</name>
      <address>
        <city>Sao Paulo</city>
        <state>São Paulo</state>
        <zip>05403-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :0760006</name>
      <address>
        <city>Sorocaba</city>
        <state>São Paulo</state>
        <zip>18040-425</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :1240003</name>
      <address>
        <city>Quebec</city>
        <zip>G1V 4W2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :1520001</name>
      <address>
        <city>Valdivia</city>
        <state>Los Ríos</state>
        <zip>5090145</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :1520005</name>
      <address>
        <city>Santiago</city>
        <state>Reg Metropolitana De Santiago</state>
        <zip>838-0418</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :1520009</name>
      <address>
        <city>Santiago</city>
        <state>Reg Metropolitana De Santiago</state>
        <zip>8380453</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :1520007</name>
      <address>
        <city>Viña del Mar</city>
        <state>Valparaíso</state>
        <zip>2520024</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :1520002</name>
      <address>
        <city>Viña del Mar</city>
        <state>Valparaíso</state>
        <zip>2520594</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :1700004</name>
      <address>
        <city>Antioquia</city>
        <zip>050010</zip>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :1700002</name>
      <address>
        <city>Cali</city>
        <zip>760043</zip>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :3480006</name>
      <address>
        <city>Budapest</city>
        <zip>1089</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :3480002</name>
      <address>
        <city>Gyula</city>
        <zip>5700</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :3480012</name>
      <address>
        <city>Mezökövesd</city>
        <zip>3400</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :3480008</name>
      <address>
        <city>Szigetvár</city>
        <zip>7900</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :3480001</name>
      <address>
        <city>Székesfehérvár</city>
        <zip>8000</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :3480003</name>
      <address>
        <city>Töröbálint</city>
        <zip>2045</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :3480007</name>
      <address>
        <city>Zalaegerszeg</city>
        <zip>8900</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :3800003</name>
      <address>
        <city>Firenze</city>
        <zip>50139</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :3800004</name>
      <address>
        <city>Padova</city>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :3800005</name>
      <address>
        <city>Roma</city>
        <zip>00146</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :3920002</name>
      <address>
        <city>Nagoya-shi</city>
        <state>Aichi</state>
        <zip>457-8511</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :3920005</name>
      <address>
        <city>Yotsukaido-shi</city>
        <state>Chiba</state>
        <zip>284-0003</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :3920008</name>
      <address>
        <city>Shibukawa-shi</city>
        <state>Gunma</state>
        <zip>377-8577</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :3920003</name>
      <address>
        <city>Sapporo-shi</city>
        <state>Hokkaido</state>
        <zip>064-0821</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :3920006</name>
      <address>
        <city>Kamakura-shi</city>
        <state>Kanagawa</state>
        <zip>247-0072</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :3920004</name>
      <address>
        <city>Ritto-shi</city>
        <state>Shiga</state>
        <zip>520-3046</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :3920001</name>
      <address>
        <city>Chuo-ku</city>
        <state>Tokyo</state>
        <zip>104-0031</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :4400005</name>
      <address>
        <city>Siauliai</city>
        <zip>LT-76231</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :4400003</name>
      <address>
        <city>Utena</city>
        <zip>LT-28151</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :4400001</name>
      <address>
        <city>Vilnius</city>
        <zip>LT-08406</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :4400004</name>
      <address>
        <city>Vilnius</city>
        <zip>LT-09108</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :4840006</name>
      <address>
        <city>Chihuahua</city>
        <zip>31000</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :4840004</name>
      <address>
        <city>Chihuahua</city>
        <zip>31200</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :4840003</name>
      <address>
        <city>Durango, Durango</city>
        <zip>34080</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :4840001</name>
      <address>
        <city>Monterrey, Nuevo León</city>
        <zip>64460</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :4840002</name>
      <address>
        <city>Veracruz</city>
        <zip>91910</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :6160001</name>
      <address>
        <city>Lodz</city>
        <state>Lódzkie</state>
        <zip>90-329</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :6160002</name>
      <address>
        <city>Poznan</city>
        <state>Wielkopolskie</state>
        <zip>60-693</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :6430004</name>
      <address>
        <city>Perm</city>
        <zip>614066</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :6430002</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>193312</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :6430001</name>
      <address>
        <city>Saint-Petersburg</city>
        <zip>194100</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :6430005</name>
      <address>
        <city>St Petersburg</city>
        <zip>197101</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :6430003</name>
      <address>
        <city>St. Petersburg</city>
        <zip>196158</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :7100001</name>
      <address>
        <city>Cape Town</city>
        <zip>7700</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :7240001</name>
      <address>
        <city>Barcelona</city>
        <state>Barcelona [Barcelona]</state>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :7920005</name>
      <address>
        <city>Adana</city>
        <zip>01339</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :7920001</name>
      <address>
        <city>Ankara</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :7920003</name>
      <address>
        <city>İstanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :7920004</name>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :8040007</name>
      <address>
        <city>Chernivtsi</city>
        <zip>58023</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :8040004</name>
      <address>
        <city>Dnipro</city>
        <zip>49101</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :8040005</name>
      <address>
        <city>Kharkiv</city>
        <zip>61093</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :8040008</name>
      <address>
        <city>Kryvyi Rig</city>
        <zip>50082</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :8040001</name>
      <address>
        <city>Kyiv</city>
        <zip>03115</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :8040002</name>
      <address>
        <city>Zaporizhzhya</city>
        <zip>69063</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :8040003</name>
      <address>
        <city>Zaporizhzhya</city>
        <zip>69076</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Brazil</country>
    <country>Canada</country>
    <country>Chile</country>
    <country>Colombia</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Lithuania</country>
    <country>Mexico</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Turkey</country>
    <country>Ukraine</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 26, 2021</verification_date>
  <study_first_submitted>March 22, 2018</study_first_submitted>
  <study_first_submitted_qc>June 6, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 18, 2018</study_first_posted>
  <last_update_submitted>October 26, 2021</last_update_submitted>
  <last_update_submitted_qc>October 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

